Glutamine enzyme inhibitor RCC is blocked

Today, U.S. biotech company Calithera announced that its main product, the glutamine enzyme inhibitor telaglenastat (CB-839), missed the first stage of the trial in a phase II clinical trial called Cantata.
the trial, which recruited 444 second-line RCC patients, compared the effects of telaglenastat and placebo on PFS in Cabometyx, Exelixis, and found no difference between the two groups (9.3 to 9.2 months, failing to achieve a statistically significant distinction).
this product is also in the process of a clinical trial with the K drug combination in KEAP1/NRF2 variant lung cancer called Keapsake, but the failure of the first adaptation is clearly not a good thing.
, which was affected by the news, fell 45 per cent today and announced 35 per cent job cuts.
drug source analysis Tumors in order to maintain their high consumption must reformulate the metabolic system of cells, in addition to balancing energy and building materials needs also produce some immunosuppressive, growth-promoting signal molecules.
Amino acids are one of the most important raw materials in the process of life, amino acid metabolites are important places for life to find new functions, and are estimated to be one of the most endogenous substances involved in reality TV screening, so it is not surprising that amino acid metabolism is pulled down by tumors.
iDO inhibitor after PD-1 is to inhibit the production of degradation tryptophan degradation products.
IDO largely faded from the pharmaceutical world after the failure of Epacadostat, other amino acid metabolases still have a strong attraction, including the diphine metabolase, a tryptophan degradation product downstream of IDO.
calA platform is mainly to interfere with the metabolism of these amino acids, in which the hydrolyzed enzyme inhibitor CB1158 is developed in cooperation with IDO leader Incyte.
RCC is a tumor with a metabolic disorder, and telaglenastat interferes with the dependence of tumor cells on glutamate.
today's trial did not screen the mutant population, and Keapsake asked for the NRF2 variant.
glutamine is an important regulatory enzyme for glutathione synthesis, which is a key reducing substance in cells and is important for controlling oxide concentrations in cells.
large molecules have many biomoleles that can be oxidized, such as protein -based, DNA, RNA, and so on, and oxidation can significantly change the function of these biomoleganics.
, , loses its pro-nuclear function when oxidized, so redox is a major mechanism for regulating in-cell ecosystems.
KEAP1/NRF2 system is one of the main regulators for cells to cope with external pressure, Reata's Nrf2 activator platform produces several near-market rare disease drugs.
about 20 percent of lung cancer patients have this path path road mutation, leading to glutathione disorders.
why CALA still has confidence in NRF2 variant lung cancer despite today's RCC failure.
amino acids in addition to metabolic enzymes is an entry point of its transport mechanism is also an intervention target, such as lysine transport protein SLC75A5 is also a therapeutic target, especially for certain breast cancers.
But interfering with tumor metabolism is no more complex than directly shutting down kinase inhibitors or fixed-point blasting ADCs, which are more complex strategies around bends, and there are currently limited success stories.
most successful should be IDH inhibitors, but despite the AA-channel listing after the validation of phase III clinical results are not good.
the RCC has been dazzled by changes in standard therapies in recent years, the process is largely limited to angiogenesic inhibitors, mTOR, and PD-1, and new agents are certainly needed.
failure of CALA not only hurts himself, but also regrets the failure to screw the amino acid metabolism screw.
。